EPISODE · Jan 27, 2026 · 13 MIN
No biotech bubble – but can the sector’s rally persist through 2026?
Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this year, according to new RBC research. Brian Abrahams, Head of Global Healthcare Research, highlights some of the classes set for new breakthroughs, and points to the potential tripwires that lie ahead as biotech looks to continue its near-historic rally.
Embed this episode
NOW PLAYING
No biotech bubble – but can the sector’s rally persist through 2026?
0:00
13:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Pathfinders in Biopharma?
This episode is 13 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on January 27, 2026.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!